Neoadjuvant Endocrine Therapy Models
Neoadjuvant therapy is therapy administered before surgical intervention and while the tumor remains in the breast. It may be given to treat large, locally advanced tumors, with the aim of shrinking them and thus making their surgical excision either simply possible or less radical. Most neoadjuvant therapy is chemotherapy, but adjuvant endocrine therapy is increasingly used in hormone-sensitive tumors; for example, those responsive to tamoxifen. Repeat biopsies aimed at assessing response to treatment—for example, by examining estrogen receptor status or markers of proliferation in tumor tissue—may be taken during the course of adjuvant therapy. In this chapter, the essential protocols associated with designing neoadjuvant trials are described, methods of assessing response to neoadjuvant therapy are detailed, and various approaches to collecting appropriate clinical samples and their assessment are presented.
- Effects of Fixation on Tissues
- Expression Analysis of Homeobox Genes in Leukemia/Lymphoma Cell Lines
- Application of SNP Genotype Arrays to Determine Somatic Changes in Cancer
- Preparation of DNA-Protein Complexes Suitable for Spectroscopic Analysis
- Animal Models of Prostate Cancer
- Immunohistochemical Detection and Quantitation of Cell Surface Receptors for Prostanoids
- The Effects of Butyrate and the Role of c-myc in N.1 Ovarian Carcinoma Cells Determined by Northern Blotting
- Conventional Cytogenetic Techniques in the Diagnosis of Childhood Acute Lymphoblastic Leukemia
- Immunoglobulin Gene Mutation Patterns and Heterogeneity of Marginal Zone Lymphoma
- MicroRNA Biogenesis and Cancer